BIA
RETA

Biondo Investment Advisors’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Biondo Investment Advisors’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-12,750
Closed -$1.3M – 83
2023
Q2 		$1.3M Buy
12,750
+9,200
+259% +$871K 0.24% 53
2023
Q1 		$323K Buy
+3,550
New +$208K 0.07% 67
2021
Q4 		– Sell
-104,120
Closed -$10.5M – 88
2021
Q3 		$10.5M Buy
104,120
+2,801
+3% +$328K 1.8% 18
2021
Q2 		$14.3M Buy
101,319
+115
+0.1% +$13K 2.46% 12
2021
Q1 		$10.1M Sell
101,204
-12,488
-11% -$1.46M 2.01% 17
2020
Q4 		$14.1M Buy
113,692
+14,040
+14% +$1.85M 2.69% 10
2020
Q3 		$9.71M Buy
99,652
+50
+0.1% +$6.25K 2.1% 13
2020
Q2 		$15.5M Buy
99,602
+12,030
+14% +$1.83M 3.92% 8
2020
Q1 		$12.6M Sell
87,572
-2,563
-3% -$495K 4.19% 7
2019
Q4 		$18.4M Buy
90,135
+16,580
+23% +$3.02M 4.25% 4
2019
Q3 		$5.91M Buy
73,555
+465
+0.6% +$39.5K 1.51% 19
2019
Q2 		$6.9M Buy
+73,090
New +$6.31M 1.64% 16

Other funds holding RETA

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Biondo Investment Advisors's RETA Position: Q3 2023 in Review

Biondo Investment Advisors sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 12,750 shares — an estimated $1.3M sold.

Biondo Investment Advisors first reported a position in RETA in Q2 2019 and held it in 12 quarters. The position peaked at $18.4M in Q4 2019. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

  • Biondo Investment Advisors reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
  • Biondo Investment Advisors sold 12,750 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $1.3M.
  • Biondo Investment Advisors first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2019 and held it in 12 quarters.
  • Biondo Investment Advisors's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $18.4M in Q4 2019.
  • 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Biondo Investment Advisors's 13F filing for Q3 2023, filed 9 Nov 2023.